Cystic Fibrosis

Overview and Epidemiology of Cystic Fibrosis

  • Definition: Cystic Fibrosis (CF) is an inherited disorder that primarily affects the body's secretory glands, which are responsible for producing mucus, digestive enzymes, and sweat.

  • Primary Affected Systems:

    • Lungs

    • Sinuses

    • Pancreas

    • Intestines

    • Liver

    • Reproductive organs

  • Epidemiological Facts:

    • Among Caucasian populations, CF occurs in approximately 11 in 2,5002{,}500 to 3,5003{,}500 infants.

    • The prevalence of CF is significantly lower among people of color.

  • Timeline of Diagnosis:

    • Diagnosis often occurs around 22 years of age or later.

    • Some individuals may remain asymptomatic for many years before clinical signs and symptoms emerge.

Pathophysiology of the CFTR Protein

  • Genetic Root: CF is caused by a mutation in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene.

  • The CFTR Protein Function:

    • Responsible for regulating the movement of chloride (Cl−Cl^-) into and out of body cells.

    • Proper regulation of chloride is essential for maintaining water balance within tissues.

    • The mutation affects not only chloride but also the movement of salt (sodium chloride or NaClNaCl) and water (H2OH_2O) across cell membranes.

  • Cellular Mechanics of Mucus Production:

    • Normal Function: CFTR protein works correctly →\rightarrow Chloride moves out of the cell →\rightarrow Water follows the chloride →\rightarrow Mucus remains thin and slippery.

    • Cystic Fibrosis Function: CFTR protein is broken or dysfunctional →\rightarrow Chloride becomes stuck inside the cell →\rightarrow Water does not follow the salt out of the cell →\rightarrow Mucus becomes abnormally thick and sticky.

  • Cellular Mechanics in Sweat Glands:

    • Normal Function: Working CFTR allows chloride to move back into the body from the sweat duct →\rightarrow Sodium follows the chloride →\rightarrow Less salt is left in the sweat on the skin surface →\rightarrow Normal sweat salt content.

    • Cystic Fibrosis Function: Broken CFTR prevents chloride from moving back into the body cells from the sweat duct →\rightarrow Sodium cannot follow →\rightarrow High concentrations of salt stay in the sweat →\rightarrow Salty-tasting sweat.

  • Consequences of Thick Mucus:

    • Obstruction of airways, pancreatic ducts, and other bodily ducts.

    • Creation of an environment that supports bacterial growth, leading to chronic infections.

    • Immune Response Involvement: White blood cells (WBCs) react to infections in the lungs. When these WBCs die, they release sticky DNA substances into the mucus, further increasing its viscosity and worsening the degree of airway obstruction, inflammation, and respiratory complications.

Genetic Transmission and Risk Factors

  • Inheritance Pattern: CF is an autosomal recessive disorder.

  • Carrier Status:

    • Parents who carry one abnormal CFTR gene and one normal gene are called carriers.

    • Carriers usually do not exhibit signs or symptoms of the disease because their single normal gene provides enough function.

  • Inheritance Probabilities (If both parents are carriers):

    • 25%25\% Chance (1 in 4): The child inherits two abnormal genes and has cystic fibrosis.

    • 50%50\% Chance (1 in 2): The child inherits one abnormal gene and one normal gene, making them a carrier only.

    • 25%25\% Chance (1 in 4): The child inherits two normal genes and is neither affected nor a carrier.

  • Prevention and Screening:

    • Genetic screening can be performed using blood and saliva samples.

    • Prenatal testing on the fetus can be conducted if both parents are known to carry abnormal genes.

Clinical Manifestations and Systemic Complications

  • Respiratory System:

    • Chronic cough and persistent infections.

    • Chronic Sinusitis: Characterized by the accumulation of nasal secretions, inflammation, and infection.

    • Bronchiectasis and Pneumonia: Recurrent infections lead to the development of scar tissue, loss of lung elasticity, and reduced lung function.

    • Pneumothorax: This can develop in the later stages of the disease.

    • Respiratory Failure: The ultimate cause of death in many cases due to cumulative damage and infection.

  • Gastrointestinal (GI) and Hepatic Systems:

    • Chronic diarrhea and nutritional deficiencies.

    • Obstruction of the bile duct (which transports bile from the liver and gallbladder to the small intestine) by thick mucus.

    • Hepatic Dysfunction: Impairment of the bile duct can lead to liver issues, including cirrhosis and gallstone formation.

    • Ammonia Build-up: Hepatic dysfunction can cause a build-up of ammonia, resulting in confusion and jaundice.

    • Steatorrhea: Bulky, fatty, and foul-smelling stools due to malabsorption.

  • Pancreas:

    • Mucus secretions obstruct pancreatic ducts, preventing the release of essential digestive enzymes.

    • Malnutrition: Inability to digest fats, proteins, and carbohydrates, leading to delayed growth and development.

    • Endocrine Issues: Interference with insulin production, which can result in Type 2 diabetes.

  • Reproductive System:

    • Males: The majority of men with CF exhibit bilateral absence of the vas deferens (the tube connecting the testes and prostate for sperm transport), leading to infertility.

    • Females: Pregnant women with CF may face significant challenges with breathing, nutrition, and liver function.

Diagnostic Testing and Procedures

  • Prenatal Testing:

    • Chorionic Villus Sampling (CVS): Performed at 1010 to 1313 weeks of gestation.

    • Amniocentesis: Performed at 1515 to 2020 weeks of gestation.

  • Infant Screening:

    • IRT Test: Analysis of a blood sample to measure levels of Immunoreactive Trypsinogen released by the pancreas.

    • Sweat Test: If IRT levels are high, a sweat test is administered between 22 and 44 weeks of age to check for high chloride levels.

  • Testing in Older Patients: Children and adults might be tested if they present with warning signs such as nasal polyps, pancreatitis, male infertility, chronic lung or sinus infections, or bronchiectasis.

Pharmacologic Therapy: Respiratory Medications

  • Bronchodilators:

    • Example: Albuterol.

    • Function: Opens the bronchioles, improves medication delivery, and assists in moving mucus secretions.

    • Usage Timing: Administered before Chest Physiotherapy (CPT) and before mucolytics or other inhaled medications.

    • Contraindication: Use with caution if the patient has a paradoxical decrease in airflow.

  • Mucolytics:

    • Used to break down the viscosity of mucus.

    • Dornase alfa (Pulmozyme):

      • Analogy: "Scissors" that cut up the "spaghetti-like" DNA strands released by dead WBCs trapped in the mucus.

      • Effect: Thins the mucus, making it easier to expectorate.

      • Side Effects: Hoarseness, voice changes, pharyngitis, and rash/hives.

      • Contraindication: Pregnancy.

    • Hypertonic Saline (7%7\% Salt Water):

      • Mechanism: High concentration of salt pulls water into the airways through osmosis (H2OH_2O follows salt).

      • Effect: Hydrates and thins the mucus.

      • Precaution: Can irritate airways and cause bronchospasm; always give a bronchodilator first to open the airways.

    • Interaction Warning: Never mix Dornase alfa and Hypertonic Saline in the same nebulizer. The salt in the hypertonic saline will inactivate the Dornase alfa enzyme.

Pharmacologic Therapy: Antibiotics and CFTR Modulators

  • Antibiotics:

    • Used to treat and prevent lung infections. Common classes include Aminoglycosides and Monobactams.

    • Tobramycin: Administered orally, IV, or inhaled; treatment courses may last up to 21/321/3 weeks.

    • Side Effects/Nursing Considerations:

      • Ringing in the ears (Ototoxicity).

      • Photosensitivity.

      • Gastrointestinal issues (Report black, tarry stools).

      • Monitoring Kidney Function (Nephrotoxicity): Check Urine output, BUN, Creatinine, and GFR. High doses are often required because absorption and digestion are impaired in CF patients.

  • Anti-inflammatory Drugs:

    • Ibuprofen: Given to reduce the accumulation of neutrophils and inflammation in the airways.

    • Monitoring: Watch for gastric bleeding, GI toxicity, and renal function impairment.

    • Warning: Never give Aspirin (due to the risk of Reye's syndrome).

  • CFTR Modulators:

    • These target the defective CFTR protein specifically to improve its activity and decrease mucus viscosity.

    • Ivacaftor: Helps the protein function correctly to allow salt and fluid to move into the airways.

    • Orkambi: A combination of Ivacaftor and Lumacaftor for patients aged 12+12+ with two copies of the F508delF508del mutation.

    • Trikafta: For patients aged 12+12+ with at least one F508delF508del mutation.

    • Administration: Should be taken twice daily with fatty foods to aid absorption.

Pharmacologic Therapy: Digestive Management

  • Pancreatic Enzyme Replacement Therapy (PERT):

    • Example: Creon.

    • Composition: Contains lipase, amylase, and protease.

    • Administration: Capsules must be taken before every meal and every snack.

    • Duration of Action: Effective for approximately 11 hour.

    • Goal: To digest carbohydrates, proteins, and fats.

  • Vitamins:

    • Supplementation of fat-soluble vitamins: ADEK (Vitamins A, D, E, and K).

Non-Pharmacologic Therapy and Lifestyle

  • Airway Clearance Techniques (ACTs):

    • Keep alveoli open and prevent pneumonia.

    • Chest Physiotherapy (CPT): Involves percussion (clapping or pounding on the chest) and postural drainage.

    • Positioning: Raising parts of the lungs to be drained using gravity (sitting or lying on the stomach).

    • Deep breathing and coughing: Patients should not suppress coughs, as coughing helps clear large airways.

    • Suctioning: Necessary for infants (oral and nasal) to prevent aspiration.

  • Nutrition and Hydration:

    • Well-balanced diet that is high in calories and high in fat.

    • Includes fruits, vegetables, and whole grains.

    • Increased salt intake is often required as salt is lost through sweat.

  • Vaccinations:

    • Essential to prevent respiratory infections (Influenza, Measles, Pertussis).

    • Rule: Patients should receive the inactivated version of heart/respiratory-related vaccines rather than live versions due to increased infection risk.

Age-Specific Considerations and Surgery

  • Infants and Children:

    • Meconium Ileus: Meconium blocks the lower digestive tract, preventing stool passage; may present with vomiting and bowel distention.

    • Intussusception: The intestine slides into itself in a "telescoping" manner.

    • Failure to Thrive: Poor weight gain and delayed growth.

    • Echogenic Bowel: An hyperechoic/obstructed intestine identified on prenatal ultrasound may trigger genetic testing.

  • Adolescents:

    • May reach puberty later than peers (1818 to 2424 months delay).

    • Need for Vitamin D and Calcium supplementation.

    • Pregnancy/Fertility: Women may require Assisted Reproductive Technology (ART), IVF, or IUI. Men may utilize intracytoplasmic sperm injection to conceive. Women are encouraged to perform Kegel exercises.

  • Surgical Options:

    • Removal of nasal polyps to improve breathing.

    • Feeding tube insertion for patients with inadequate nutrition.

    • Bowel surgery for blockages.

    • Transplantation: Lung transplantation for antibiotic-resistant complications; may also involve liver or pancreas transplants. Post-transplant care requires life-long immunosuppressants.